Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200287461> ?p ?o ?g. }
- W4200287461 endingPage "1268" @default.
- W4200287461 startingPage "1268" @default.
- W4200287461 abstract "Drug repositioning has recently emerged as a strategy for developing new treatments at low cost. In this study, we used a library of approved drugs to screen for compounds that suppress cardiomyocyte hypertrophy. We identified the antiplatelet drug sarpogrelate, a selective serotonin-2A (5-HT2A) receptor antagonist, and investigated the drug's anti-hypertrophic effect in cultured cardiomyocytes and its effect on heart failure in vivo. Primary cultured cardiomyocytes pretreated with sarpogrelate were stimulated with angiotensin II, endothelin-1, or phenylephrine. Immunofluorescence staining showed that sarpogrelate suppressed the cardiomyocyte hypertrophy induced by each of the stimuli. Western blotting analysis revealed that 5-HT2A receptor level was not changed by phenylephrine, and that sarpogrelate suppressed phenylephrine-induced phosphorylation of ERK1/2 and GATA4. C57BL/6J male mice were subjected to transverse aortic constriction (TAC) surgery followed by daily oral administration of sarpogrelate for 8 weeks. Echocardiography showed that 5 mg/kg of sarpogrelate suppressed TAC-induced cardiac hypertrophy and systolic dysfunction. Western blotting revealed that sarpogrelate suppressed TAC-induced phosphorylation of ERK1/2 and GATA4. These results indicate that sarpogrelate suppresses the development of heart failure and that it does so at least in part by inhibiting the ERK1/2-GATA4 signaling pathway." @default.
- W4200287461 created "2021-12-31" @default.
- W4200287461 creator A5006424330 @default.
- W4200287461 creator A5017026237 @default.
- W4200287461 creator A5018603644 @default.
- W4200287461 creator A5030601047 @default.
- W4200287461 creator A5035471147 @default.
- W4200287461 creator A5043372218 @default.
- W4200287461 creator A5043657069 @default.
- W4200287461 creator A5046141573 @default.
- W4200287461 creator A5046622681 @default.
- W4200287461 creator A5062452954 @default.
- W4200287461 creator A5066054971 @default.
- W4200287461 creator A5072002120 @default.
- W4200287461 creator A5073729808 @default.
- W4200287461 creator A5074627346 @default.
- W4200287461 creator A5078982756 @default.
- W4200287461 date "2021-12-05" @default.
- W4200287461 modified "2023-09-27" @default.
- W4200287461 title "The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway" @default.
- W4200287461 cites W1974083026 @default.
- W4200287461 cites W1977483151 @default.
- W4200287461 cites W1978821056 @default.
- W4200287461 cites W1981219119 @default.
- W4200287461 cites W1983508581 @default.
- W4200287461 cites W1987059560 @default.
- W4200287461 cites W1993243592 @default.
- W4200287461 cites W1996703245 @default.
- W4200287461 cites W2006020938 @default.
- W4200287461 cites W2006224306 @default.
- W4200287461 cites W2009813647 @default.
- W4200287461 cites W2012746420 @default.
- W4200287461 cites W2028293449 @default.
- W4200287461 cites W2033374420 @default.
- W4200287461 cites W2034569019 @default.
- W4200287461 cites W2050182552 @default.
- W4200287461 cites W2052780003 @default.
- W4200287461 cites W2055123579 @default.
- W4200287461 cites W2061463522 @default.
- W4200287461 cites W2065417808 @default.
- W4200287461 cites W2066113694 @default.
- W4200287461 cites W2076738002 @default.
- W4200287461 cites W2085139899 @default.
- W4200287461 cites W2101085693 @default.
- W4200287461 cites W2104640964 @default.
- W4200287461 cites W2116932184 @default.
- W4200287461 cites W2131845563 @default.
- W4200287461 cites W2132860970 @default.
- W4200287461 cites W2135194780 @default.
- W4200287461 cites W2136070250 @default.
- W4200287461 cites W2144766684 @default.
- W4200287461 cites W2145852350 @default.
- W4200287461 cites W2152642467 @default.
- W4200287461 cites W2155591792 @default.
- W4200287461 cites W2165207985 @default.
- W4200287461 cites W2165672775 @default.
- W4200287461 cites W2292493149 @default.
- W4200287461 cites W2341605660 @default.
- W4200287461 cites W2407616088 @default.
- W4200287461 cites W2509110262 @default.
- W4200287461 cites W2519289623 @default.
- W4200287461 cites W2607257758 @default.
- W4200287461 cites W2742106475 @default.
- W4200287461 cites W2745289695 @default.
- W4200287461 cites W2784335907 @default.
- W4200287461 cites W2794129391 @default.
- W4200287461 cites W2796168841 @default.
- W4200287461 cites W2800595743 @default.
- W4200287461 cites W2889140275 @default.
- W4200287461 cites W2889654052 @default.
- W4200287461 cites W2892573831 @default.
- W4200287461 cites W2941734350 @default.
- W4200287461 cites W3019091287 @default.
- W4200287461 cites W3042040578 @default.
- W4200287461 cites W3091490365 @default.
- W4200287461 cites W3126754513 @default.
- W4200287461 cites W3129054508 @default.
- W4200287461 cites W3129189594 @default.
- W4200287461 cites W3159743438 @default.
- W4200287461 cites W3163421167 @default.
- W4200287461 cites W3181235686 @default.
- W4200287461 cites W3183989129 @default.
- W4200287461 cites W4211150832 @default.
- W4200287461 doi "https://doi.org/10.3390/ph14121268" @default.
- W4200287461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34959669" @default.
- W4200287461 hasPublicationYear "2021" @default.
- W4200287461 type Work @default.
- W4200287461 citedByCount "3" @default.
- W4200287461 countsByYear W42002874612022 @default.
- W4200287461 countsByYear W42002874612023 @default.
- W4200287461 crossrefType "journal-article" @default.
- W4200287461 hasAuthorship W4200287461A5006424330 @default.
- W4200287461 hasAuthorship W4200287461A5017026237 @default.
- W4200287461 hasAuthorship W4200287461A5018603644 @default.
- W4200287461 hasAuthorship W4200287461A5030601047 @default.
- W4200287461 hasAuthorship W4200287461A5035471147 @default.
- W4200287461 hasAuthorship W4200287461A5043372218 @default.
- W4200287461 hasAuthorship W4200287461A5043657069 @default.